Clinical Applications of Tumor Immunotherapy

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Oncology".

Deadline for manuscript submissions: 16 September 2024 | Viewed by 1135

Special Issue Editors


E-Mail Website
Guest Editor
Department of Specialized, Experimental and Diagnostic Medicine, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
Interests: neuroendocrine tumors; small-cell lung cancer; immunotherapy; clinical research; precision oncology
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Specialized, Experimental and Diagnostic Medicine, S.Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
Interests: neuroendocrine tumors; small-cell lung cancer; immunotherapy; clinical research; precision oncology

Special Issue Information

Dear Colleagues,

The advent of tumor immunotherapy had a significant impact on the treatment landscape of several hematological and solid tumors. The use of immune checkpoint inhibitors (ICIs) is by far the strategy with the most dramatic impact and widest adoption in tumor immunotherapy. These agents block inhibitory interactions between cancer and immune cells, thus prompting antitumor immunity and averting tumor evasion of the immune response. Adoptive cell therapies, such as chimeric antigen receptor T (CAR-T) cells, have been proven to be effective in some hematologic malignancies, with uncertain results in solid tumors. Several other tumor immunotherapy approaches, e.g., therapeutic vaccines and bispecific T cell engagers (BiTE), among others, are actively investigated, with promising results.

Irrespective of the type considered, tumor immunotherapies yielded unprecedented benefits in hard-to-treat tumors in terms of long-lasting responses and the prolongation of survival outcomes, with a peculiar toxicity profile that can be insidious. Research on tumor immunotherapy is brisk and active, currently focusing on how to increase the proportion of patients that benefit from different immunotherapy approaches and on identifying predictive biomarkers of response; thus, it is critical to understand how available evidence and findings, as well as future perspectives, translate into resources for clinical practice.

Dr. Giuseppe Lamberti
Dr. Elisa Andrini
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • immunotherapy
  • PD-1/PD-L1
  • CTLA-4
  • novel biomarkers
  • personalized oncology
  • tumor vaccine
  • cell therapy
  • adoptive immunotherapy
  • T cell engagers

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 816 KiB  
Article
A Systemic Immune Inflammation Index and PD-L1 (SP142) Expression as a Potential Combined Biomarker of the Clinical Benefit of Chemo-Immunotherapy in Extensive-Stage Small-Cell Lung Cancer
by Jong-Min Baek, Hyungkeun Cha, Yeonsook Moon, Lucia Kim, Seung Min Kwak, Eun Sun Park and Hae-Seong Nam
J. Clin. Med. 2024, 13(5), 1521; https://doi.org/10.3390/jcm13051521 - 6 Mar 2024
Viewed by 940
Abstract
Background: No studies have identified combined biomarkers that may be more reasonable for the assessment of current chemo-immunotherapy in patients with extensive stage small-cell lung cancer (ES-SCLC). Methods: This study was conducted to investigate a combined biomarker with prognostic or predictive [...] Read more.
Background: No studies have identified combined biomarkers that may be more reasonable for the assessment of current chemo-immunotherapy in patients with extensive stage small-cell lung cancer (ES-SCLC). Methods: This study was conducted to investigate a combined biomarker with prognostic or predictive value in ES-SCLC. We determined the best independent prognostic biomarker among the four complete blood-count-derived inflammatory biomarkers (CBC-IBs). Subsequently, we analyzed the prognostic or predictive value of combining this independent CBC-IB with PD-L1 (SP142) expression. We prospectively assessed the SP142 analyses in tumor samples at diagnosis. Results: All in all, 55 patients with ES-SCLC were classified into four groups according to the systemic immune inflammation index (SII) (low/high) and SP142 (positive/negative). The best survival was observed in the low-SII/ SP142-positive group, whereas the worst survival was observed in the high-SII/SP142-negative group (p = 0.002). The combined SII-SP142 biomarker was better for predicting both survival and disease progression in patients with ES-SCLC. Conclusions: The combined SII-SP142 biomarker can be readily and universally obtained at a low cost in clinical practice, without requiring advanced genomics technology or specialized expertise. Although further studies are needed to confirm that the combined SII-SP142 biomarker is widely applicable, it should help clinicians to identify the best patients for combined chemotherapy with atezolizumab in ES-SCLC. Full article
(This article belongs to the Special Issue Clinical Applications of Tumor Immunotherapy)
Show Figures

Figure 1

Back to TopTop